Angelini Pharma takes center stage at the 15th European Epilepsy Congress in Rome
Organised by the International League Against Epilepsy (ILAE) and held biennially between 7th and 11th September, Angelini Pharma is proud to announce its participation in the 15th European Epilepsy Congress (EEC).
Bringing together researchers, clinicians and key opinion leaders to network and discuss the latest developments in basic and clinical epileptology, the 15th EEC will be held at La Nuvola Convention Centre in Rome.
Angelini Pharma’s role as a key participant will involve a significant commitment to the congress, including sponsoring 2 satellite symposia, presenting 3 posters on cenobamate, setting up a 70sqm booth — one of the largest at the Congress — in the exhibition area, and having over 300 company delegates in attendance. The publication of 28 independent posters on Cenobamate — an anti-seizure medication approved in Europe as an adjunctive treatment for focal-onset seizures in adult epilepsy patients — will also highlight the strong interest of the international community in the Angelini Pharma active ingredient.
Programmed for Sunday 8th September, the first symposium will respond to the abstract: Seizure freedom: Is the theory matching the practice? Chaired by Simona Lattanzi MD PhD, Angelini Pharma invites Shanika Samarasekera MD, Prof. Vicente Villanueva and Prof. Bernhard Steinhoff who, after their corresponding presentations, will join a panel discussion and Q&A session. Presenting an overview of the importance of seizure freedom and the barriers to achieving it from the varied perspectives of healthcare professionals, patients and their families/caregivers, Prof. Lattanzi will welcome and introduce the panel — with Dr.Samarasekera set to speak on the management of anti-seizure medication and tolerability; Prof. Villanueva on how to maximize the efficacy while simplifying treatment; and Prof. Steinhoff on nihilism and over-treatment.
Programmed for Monday 9th September, a second symposium will respond to the abstract: Seizures beget more than seizures: the impact of uncontrolled epilepsy. Chaired by Adam Strzelczyk MD PhD, Angelini Pharma invites Prof. Matthew Walker and Marian Galovic MD PhD to join the event for another panel discussion and Q&A session. Presenting an overview of the impact of seizures from an individual to a society level, Prof. Strzelczyk will welcome and introduce the panellists — with Prof. Walker sharing a zoomed in approach on the impact of seizures on a cellular and network level, including the effect of recurrent seizures on cell loss, connectivity and modifications to the seizure threshold; and Dr. Galovic on brain structure and function, including impairments in higher order brain functions, progressive atrophy and changes to cognition.
Angelini Pharma’s extensive participation in the 15th EEC signifies its steadfast commitment to epilepsy, which affects an estimated 50 million individuals globally. Calling to attention the long-term data on cenobamate and the positive findings on its sustained benefit in adults living with epilepsy, Rafal Kaminski (Chief Scientific Officer, Angelini Pharma) affirms: “Our aim is to enhance the management of seizures, increase the accessibility and tolerability of treatments, ultimately achieving seizure-freedom for people living with epilepsy.”